It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > MHLW Expert Panel on Comprehensive Policies
MHLW Expert Panel on Comprehensive Policies
-
Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
-
Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
-
Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
-
Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
-
Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
-
Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
-
NHI-Market Price Gap at 20-Plus-Outlet Pharmacies 1.8 Times Larger vs. Small Hospitals
October 14, 2022
-
Experts Urge MHLW to Present Detailed Data on Generic Manufacturing Costs
October 13, 2022
-
Ways to Resolve Drug Lag/Loss, Fuel Development in Japan Up for Debate: MHLW Panel
October 13, 2022
-
Panel Members Want More Data on Allocation of NHI-Market Price Margins
October 13, 2022
-
MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
-
Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
-
Crecon President Sounds Alarm over Hollowing-Out of Domestic Manufacturing
September 30, 2022
-
Trade Group Calls for New Pricing Model for Regenerative Medicine Products
September 30, 2022
-
2% Buffer Zone Has Multiple Functions, Should Not Be Reduced: JPWA
September 30, 2022
-
Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
Cost Rates of Drugs in Japan Worsen on Inflation, Weaker Yen: FPMAJ Survey
September 26, 2022
-
Japan, US, European Trade Groups Eye Introduction of “Official Margins” in Price Revision Review
September 26, 2022
-
Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
September 26, 2022
-
Japan Generic Industry Prods Govt to Raise Drug Prices to Ensure Stable Supply
September 26, 2022
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…